Compare the best healthcare and pharma funds in India - Nippon India Pharma, SBI Healthcare Opportunities, DSP Healthcare, Mirae Asset Healthcare and HDFC Pharma. Pure play on India's pharma sector. Live NAV from RightAdvise.
Sorted by 5-year CAGR. Click any fund for full analysis - rolling returns, drawdown chart, NAV history and risk ratios.
If you had invested ₹1 lakh 5 years ago in each fund, here is how much it would be worth today. Calculated from 5 years of daily NAV in the RightAdvise database.
💡 What is AAUM? AAUM stands for Average Assets Under Management - the average value of all investor money a fund managed during a specific quarter. Reported to SEBI every quarter via AMFI. More reliable than a single-day AUM snapshot.
| Fund | NAV | AAUM | 1Y Return | 3Y CAGR | 5Y CAGR | 10Y CAGR | Max Drawdown | Sharpe (3Y) |
|---|---|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities Fund | ₹550.88 2026-06-19 | ₹3.8K Cr Jan–Mar 2026 | +12.2% | +24.8 % p.a. | +17.1 % p.a. | +14.7 % p.a. | -28.6% | 1.59 |
| Mirae Asset Healthcare Fund | ₹48.06 2026-06-19 | ₹2.7K Cr Jan–Mar 2026 | +13.2% | +24.9 % p.a. | +15.7 % p.a. | - | -20.0% | 1.56 |
| DSP Healthcare Fund | ₹46.12 2026-06-18 | ₹3.0K Cr Jan–Mar 2026 | +8.9% | +22.4 % p.a. | +15.6 % p.a. | - | -21.7% | 1.53 |
| Nippon India Pharma Fund | ₹609.41 2026-06-19 | ₹7.9K Cr Jan–Mar 2026 | +6.5% | +21.6 % p.a. | +13.7 % p.a. | +16.3 % p.a. | -21.2% | 1.44 |
| HDFC Pharma and Healthcare Fund | ₹20.62 2026-06-19 | ₹1.9K Cr Jan–Mar 2026 | +20.0% | - | - | - | -14.9% | - |
Healthcare and Pharma Funds are sectoral funds that must invest at least 80% of their assets in equity of healthcare and pharmaceutical sector companies. This includes pharmaceutical manufacturers, hospitals, diagnostic companies, medical device makers, healthcare IT firms and healthcare services companies. These are high-concentration sector funds with unique risk characteristics.
Healthcare and Pharma funds invest in one of India's most globally competitive export sectors. India is the world's largest supplier of generic medicines - providing 20% of global generic medicine exports by volume. Indian pharma companies supply medicines to over 200 countries. The domestic healthcare sector is also growing rapidly with rising health insurance penetration, hospital network expansion and increasing health awareness post-COVID. This dual tailwind - global generic pharma exports and domestic healthcare growth - makes the sector attractive for long-term investors.
The healthcare sector has unique defensive characteristics - people need medicines regardless of economic cycles. This makes pharma stocks more resilient during economic slowdowns compared to cyclical sectors like banking or infrastructure. However, pharma funds face specific risks: US FDA regulatory actions can wipe out 20-30% of a company's value overnight, drug pricing pressure in the US market compresses margins, and patent cliffs can reduce revenues when blockbuster drugs lose exclusivity. Active fund management in the pharma sector requires deep scientific and regulatory expertise.
The biggest single risk in Indian pharma funds is US FDA regulatory action. When the US Food and Drug Administration issues an import alert or warning letter to an Indian pharma plant, the affected company cannot export medicines from that facility to the US - often its largest market. This can cause the company's stock to fall 20-30% in a single day. Since pharma sector funds hold multiple Indian pharma companies, a single FDA action on a major holding can significantly impact the fund's NAV. Fund managers mitigate this by diversifying across multiple companies and monitoring FDA inspection history.
New fund analysis, articles and market insights - no spam, no selling. Unsubscribe anytime.
Found this useful? Share it